Lytix Biopharma AS - New share capital registered

14 Jan 2026 17:08 CET

Oslo, Norway, 14 January 2026: Reference is made to the stock exchange
announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 9
January 2026 regarding the successful completion of a private placement (the
"Private Placement") of new shares, raising approximately NOK 61 million in
gross proceeds.

The share capital increase relating to the Private Placement has been registered
today with the Norwegian Register of Business Enterprises. In total, 6,826,200
shares (the "Offer Shares") have been issued through the Private Placement. The
Company's new share capital is NOK 7,508,820.20, divided into 75,088,202 shares,
each with a par value of NOK 0.10.

The Offer Shares are expected to be registered in the Norwegian Central
Securities Depository (VPS) either today, 14 January 2026, or tomorrow, 15
January 2026.

Disclosure regulation:

This information is subject to a duty of disclosure pursuant to the Company's
continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

More information:
Access the news on Oslo Bors NewsWeb site